{
    "patientInformation": {
        "name": "Sarah Miller",
        "mrn": "MC-001001",
        "dateOfBirth": "1962-03-15",
        "age": 63,
        "sex": "Female"
    },
    "presentingComplaint": "Severe fatigue, jaundice, epigastric pain, confusion, and oral mucosal ulcerations.",
    "medicalHistory": {
        "conditions": [
            "Rheumatoid arthritis",
            "Essential hypertension",
            "Mild chronic kidney disease",
            "Chronic low back pain"
        ],
        "allergies": [
            "Penicillin (rash)"
        ],
        "socialHistory": "Drinks ~7-14 units/week (alcohol). Ex-smoker (quit 2017, 20 pack-year history). Retired carpenter."
    },
    "medications": {
        "chronicPriorToEvent": [
            "Methotrexate 20 mg weekly",
            "Folic Acid 5 mg weekly",
            "Lisinopril 10 mg daily"
        ],
        "initiatedAtAcuteEvent": "Trimethoprim-Sulfamethoxazole 800/160 mg BID (started 2025-06-15)"
    },
    "keyLaboratoryFindings": {
        "encounterDate": "2025-06-21",
        "results": [
            {
                "test": "ALT (SGPT)",
                "value": "1650 U/L",
                "flag": "High",
                "reference": "7.0 - 56",
                "note": "↑↑↑"
            },
            {
                "test": "AST (SGOT)",
                "value": "2100 U/L",
                "flag": "High",
                "reference": "8.0 - 40",
                "note": "↑↑↑"
            },
            {
                "test": "Alkaline Phosphatase",
                "value": "350 U/L",
                "flag": "High",
                "reference": "40 - 150",
                "note": "↑"
            },
            {
                "test": "Total Bilirubin",
                "value": "12.5 mg/dL",
                "flag": "High",
                "reference": "0.2 - 1.2",
                "note": "↑↑"
            },
            {
                "test": "Direct Bilirubin",
                "value": "8.9 mg/dL",
                "flag": "High",
                "reference": "<0.3",
                "note": "↑↑↑"
            },
            {
                "test": "INR",
                "value": "1.0",
                "flag": "",
                "reference": "0.8 - 1.2"
            },
            {
                "test": "Creatinine",
                "value": "1.5 mg/dL",
                "flag": "High",
                "reference": "0.7 - 1.3"
            },
            {
                "test": "eGFR",
                "value": "58 mL/min/1.73m2",
                "flag": "Low",
                "reference": ">60"
            },
            {
                "test": "WBC",
                "value": "5.0 x10^9/L",
                "flag": "",
                "reference": "4.0 - 10.0"
            },
            {
                "test": "Platelets",
                "value": "165 x10^9/L",
                "flag": "",
                "reference": "150 - 450"
            },
            {
                "test": "Ammonia",
                "value": "18 umol/L",
                "flag": "",
                "reference": "11.0 - 32"
            }
        ]
    },
    "diagnosis": {
        "main": "Drug-Induced Liver Injury (DILI) with Acute Liver Failure",
        "causality": "Likely idiosyncratic hepatocellular DILI caused by Trimethoprim-Sulfamethoxazole, with Methotrexate as a significant contributing factor due to potential synergistic hepatotoxicity. Patient's age, regular alcohol consumption, and mild CKD are additional risk factors.",
        "mechanism": "Trimethoprim-Sulfamethoxazole is a known hepatotoxin. Its interaction with Methotrexate, a known hepatotoxic agent, may have potentiated liver injury. Chronic alcohol consumption further increases the risk of DILI and may impair recovery."
    },
    "differentialDiagnosisTracker": {
        "diagnoses": [
            {
                "name": "Trimethoprim-Sulfamethoxazole-induced DILI",
                "status": "PRIMARY",
                "notes": "Strong temporal association, characteristic hepatocellular injury pattern, and known hepatotoxicity of TMP-SMX."
            },
            {
                "name": "Methotrexate toxicity",
                "status": "PRIMARY",
                "notes": "Contributing factor due to chronic use and potential interaction with TMP-SMX. Known hepatotoxin."
            },
            {
                "name": "Acute viral hepatitis (HAV, HBV, HCV)",
                "status": "INVESTIGATE",
                "notes": "Serologies are pending. Low pre-test probability but must be excluded."
            },
            {
                "name": "Autoimmune Hepatitis",
                "status": "INVESTIGATE",
                "notes": "No specific history, but may present with similar enzyme patterns. Autoimmune markers pending."
            },
            {
                "name": "Alcoholic Hepatitis",
                "status": "INVESTIGATE",
                "notes": "History of regular alcohol use, but acute presentation is more suggestive of DILI. Needs to be considered in context of liver disease."
            }
        ],
        "ruledOut": []
    },
    "easlAssessment": {
        "overallImpression": "Sarah Miller, a 63-year-old female, presents with severe hepatocellular DILI and meets criteria for acute liver failure. The highly probable causative agent is Trimethoprim-Sulfamethoxazole (TMP-SMX), initiated 6 days prior to presentation, with Methotrexate serving as a significant contributing factor due to potential synergistic hepatotoxicity. Her age, regular alcohol consumption, and mild chronic kidney disease are additional risk factors. The presentation with jaundice and hepatic encephalopathy necessitates urgent management and intensive monitoring.",
        "diliDiagnosticCriteriaMet": [
            {
                "criterion": "ALT ≥ 5 × ULN",
                "status": "MET",
                "details": "ALT is 1650 U/L, with an assumed ULN of 56 U/L, which is >5x ULN."
            },
            {
                "criterion": "ALT ≥ 3 × ULN with Bilirubin ≥ 2 × ULN",
                "status": "MET",
                "details": "ALT (1650 U/L) is >3x ULN (56 U/L) and Total Bilirubin (12.5 mg/dL) is >2x ULN (assumed 1.2 mg/dL)."
            }
        ],
        "causativeAgentAssessment": [
            {
                "agent": "Trimethoprim-Sulfamethoxazole",
                "role": "HIGHLY SUSPECTED PRIMARY TRIGGER",
                "rationale": "Strong temporal association: symptoms began ~4-6 days after initiation and acute presentation occurred 6 days post-initiation. TMP-SMX is a well-documented cause of idiosyncratic DILI. Its use in conjunction with methotrexate can lead to synergistic hepatotoxicity."
            },
            {
                "agent": "Methotrexate",
                "role": "SIGNIFICANT CONTRIBUTOR",
                "rationale": "Chronic use of methotrexate (20 mg weekly) is associated with drug-associated fatty liver disease (DAFLD) and can contribute to hepatotoxicity. TMP-SMX can inhibit methotrexate metabolism, potentially increasing its toxicity. Patient's age and alcohol consumption further increase risk."
            },
            {
                "agent": "Lisinopril",
                "role": "POSSIBLE CONTRIBUTOR",
                "rationale": "Lisinopril is listed as a drug associated with idiosyncratic DILI. While less likely the primary cause of the acute severe presentation, it is prudent to consider its potential contribution in the context of severe liver injury."
            }
        ],
        "severityAssessment": {
            "overallSeverity": "SEVERE DILI (Acute Liver Failure)",
            "features": [
                "Jaundice (Total Bilirubin 12.5 mg/dL)",
                "Hepatic Encephalopathy (Disorientation, Asterixis, GCS 13)",
                "Marked Transaminitis (ALT 1650 U/L, AST 2100 U/L)",
                "Coagulopathy (INR 1.0, although this requires close trend monitoring)",
                "Oral mucosal ulcerations (consistent with methotrexate toxicity)"
            ],
            "prognosisNote": "The patient meets criteria for acute liver failure, indicating a high risk of severe outcomes. Intensive monitoring and management in an ICU setting are critical for potential recovery."
        },
        "exclusionOfAlternativeCausesRequired": [
            "Viral hepatitis (HAV, HBV, HCV, HEV)",
            "Autoimmune hepatitis",
            "Alcoholic hepatitis",
            "Biliary obstruction",
            "Ischemic hepatitis",
            "Sepsis with multiorgan dysfunction"
        ],
        "localGuidelinesComparison": {
            "status": "GAP IDENTIFIED",
            "details": "Local guidelines provide general advice on alcohol consumption (limiting intake, two alcohol-free days) and medication monitoring (LFTs) in liver disease. However, they do not offer specific protocols for acute DILI management, such as immediate drug discontinuation or a systematic approach to ruling out alternative causes, which are comprehensively addressed by EASL guidelines. Therefore, EASL guidelines are primary for DILI management, complemented by local guidance on alcohol cessation and monitoring."
        },
        "references": [
            "EASL Clinical Practice Guidelines: Drug-induced liver injury-Introduction to DILI Classification",
            "EASL Clinical Practice Guidelines: Drug-induced liver injury-Retrospective Studies",
            "EASL Clinical Practice Guidelines: Drug-associated Fatty Liver Disease (DAFLD)",
            "EASL Clinical Practice Guidelines: Drug-induced liver injury-Alcohol and Pregnancy",
            "EASL Clinical Practice Guidelines: Drug-induced liver injury-Laboratory Workup for Excluding Alternative Causes",
            "Alcohol and the Liver (Local Guideline)",
            "Tacrolimus for the treatment of autoimmune liver disease (Local Guideline)"
        ]
    },
    "zone": "dili-analysis-zone"
}